GlassScriptPhysician profile
Paul Leiphart
NPI 1417586363
$3,057.35
in general payments reported to CMS, 2019-2025
14 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $354 · 2023: $859 · 2024: $789 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.15 |
| Education | $218.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $642.97 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $590.73 | 2021-2025 | |
| Ucb, INC. | $451.83 | 2022-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $344.64 | 2022-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $223.18 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $200.42 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $141.49 | 2022-2025 | |
| Genzyme Corporation | $138.67 | 2024 | |
| Sun Pharmaceutical Industries INC. | $99.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.41 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $79.21 | 2024 | Dupixent |
| Lilly USA, LLC | $19.09 | 2025 | Taltz, Ebglyss |
| Leo Pharma INC. | $13.55 | 2025 | Spevigo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Leiphart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.